Collaboration Agreement with Pharming Group N.V. - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended
	Jul. 01, 2021	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total consideration		$ 143,711
Strategic Collaboration Agreement with Pharming
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cash upfront payment received	$ 10,000
Non-refundable up-front payment	10,000
Strategic Collaboration Agreement with Pharming | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments receivable	$ 189,500
Share Purchase Agreement with Pharming
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of ordinary shares	1,227,738
Total consideration	$ 7,500
Common stock consideration	4,100
Premium consideration	3,400
Pharming Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total upfront payments	17,500
Upfront payments attributed to equity sold	4,100
Upfront payments attributed to research activities	13,400
Shares issued as part of license agreement	4,100
Excess proceeds from fair value of shares issued allocated to collaboration agreement	$ 3,400
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 11,400
Collaborative Arrangement | Accounts Receivable
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable			$ 500	$ 800